Lepton Pharmaceuticals announces that it has filed a US application with the US Patent Office entitled METHODS FOR ENHANCED GENOME EDITING The Patent application covers Lepton’s breakthrough Universal genome editing framework. It is a novel homology directed repair (HDR)-based knock-in (KI) technology named Targeted Replacement Locus Editing (TRIPLE). Precise genome editing is limited by the...

LEPTON Pharmaceuticals LTD and TAmiRNA GmbH enhance their collaboration by entering into a second agreement for discovery of epigenetic pathways related to microRNAs activities in immune cell therapy.   Lepton Pharmaceuticals LTD (Lepton), a biopharmaceutical company, focused on discovery and development of novel treatments for unmet medical needs, exploiting the subtle silencing of coding RNA...

LEPTON ANNOUNCED THAT IT COMPLETED THE FILING FOR AN ADDITIONAL PATENT APPLICATION WHICH DESCRIBES AND CLAIMS EXTENDING THE USAGE OF ITS CASTLING BREAKTHROUGH TECHNOLOGIES FOR ENHANCING THE THERAPEUTIC EFFICACY OF IMMUNE CELLS DERIVED FROM iPSC CELLS The patent application, U.S. Provisional Patent Application No. 63/520,949, is entitled METHODS FOR ENHANCING THERAPEUTIC EFFICACY OF ISOLATED CELLS...

License allows Lepton, with their proprietary Castling Technology, to develop and commercialize products and services using CRISPR/Cas9 technology Dublin, Ireland and Zichron Yakov, Israel, 26 July 2022: ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with Lepton Pharmaceuticals LTD (‘Lepton”). This is a non-exclusive licensing agreement granting Lepton access to the...

Lepton is pleased to announce that the Company has signed a consulting agreement with Dr. Elena Sotillo, Senior Research Scientist at the lab of Prof. Crystal Mackall, the Ernest and Amelia Gallo Family Professor of Pediatrics and Medicine at Stanford University and founding director of the Center for Cancer Cell Therapy, Stanford Cancer Institute, Palo...

Lepton is proud to announce that Prof. Malcolm K Brenner, M.D., Ph.D. at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX US and  Fayez Sarofim Distinguished Service Professor at Baylor College of Medicine in the Departments of Medicine, Pediatrics, and Human and Molecular Genetics. agreed to consult to Lepton for...

Lepton is pleased to announce that the Company has signed a consulting agreement with Dr. Paz Einat for consulting services in the field of development of Lepton’s developmental pharmaceutical therapeutics based on siRNA and/or miRNA.  Dr. Paz Einat is an expert in molecular biology in general (vectorology, gene expression, genomics, directed evolution and more) and...

Lepton announces filing of a PCT application covering its proprietary breakthrough Castling Technology Lepton Pharmaceuticals announces that it has filed a PCT application with the US Patent Office entitled METHODS FOR ENHANCING THERAPEUTIC EFFICACY OF ISOLATED CELLS FOR CELL THERAPY. The Patent application covers Lepton’s breakthrough Castling technology, which is, in essence, the manipulation/engineering of...